Experts Video Reports: Immuno-Oncology track

Learn about key results illustrated by slides from the sessions!

The Immuno-Oncology track 2019 is supported with a grant from Roche . The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.


ESMO Congress 2019: Expert Video Report on immune checkpoint inhibitors in MSI-High tumours

Reporting from ESMO Congress 2019, Christophe Tournigand comments on results from the subgroup, pooled and cohort analysis in the studies that show improvements in the response rate and overall survival with immune checkpoint inhibitors treatment in patients with Microsatellite Instability (MSI)-high tumours. He emphasizes the importance of MSI testing in patients with gastrointestinal, endometrial and other cancer types.

ELCC 2019: Expert Video Report on integrating Immunotherapy in the multidisciplinary board

Reporting from ELCC 2019 in Geneva, D. de Ruysscher explains that the addition of durvalumab to standard therapy has significantly improved the outcome of patients with unresectable stage III Non-Small Cell Lung Cancer. He calls for its integration into the management plan through the multidisciplinary board.


  • LBA2: Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, Stage III NSCLC (PACIFIC)– (Marina Garassino)
  • ID4: My patient needs chemoradiotherapy and durvalumab – (De Ruysscher D.)

AACR 2019: Expert Video Report on Novel Immunotherapeutics

Reporting from AACR 2019 in Atlanta, G. Curigliano comments on immunotherapy novelties, including results with novel drugs and immunotherapeutic combinations, and including association with established treatment such as radiotherapy.

AACR 2019: Expert Video Report on NSCLC

Reporting from AACR 2019 in Atlanta, M. Garassino comments on two studies about the immunotherapy outcomes in NSCLC patients presenting with brain or liver metastasis, and the use of Tumour Mutational Burden as a biomarker in metastatic NSCLC patients.

ASCO GU 2019: Expert Video Report on Renal Cell Carcinoma

Reporting from ASCO GU, Bradley McGregor comments on Renal cell carcinoma studies results: JAVELIN, KEYNOTE-426, CheckMate 214, KEYNOTE-427 and a phase II study of atezolizumab and bevacizumab


Track 2018: Videos reports from ESMO Congress

Expert Video Report on Immunotherapy for Head and Neck Cancer

Dr. Marco Merlano comments on the findings from the KEYNOTE-048 trial and an academic trial comparing bio-radiotherapy with chemo-radiotherapy in oropharyngeal cancer presented at ESMO 2018 Congress.

Expert Video Report on Immunotherapy for Colorectal Carcinoma

Commenting on the findings from CheckMate142, MODUL and NICHE studies presented at ESMO 2018 Congress, Dr Konstantinos Kamposioras says that very interesting results were presented on immunotherapy in colorectal cancer in both primary treatment and neoadjuvant settings. Results for first-line immunotherapy combination in MSI-high patients are positive both for progression-free and overall survival, but the results from immunotherapy after induction chemotherapy in BRAFwt metastatic CRC patients are inconclusive. He concludes that practice is changing and immunotherapy is approaching the first-line treatment. However, further studies are needed to confirm the outcomes reported at ESMO 2018 Congress in Munich. The results in the neoadjuvant setting are promising and potentially practice changing in terms of further improvement of survival in CRC patients.

Expert Video Report on Immunotherapy for Advanced NSCLC

Commenting on the findings from KEYNOTE-407 in metastatic squamous NSCLC and IMpower132 in metastatic non-squamous NSCLC studies presented at ESMO 2018 Congress, Dr. Silvia Novello explains that these trials show the activity of the combination therapy, chemotherapy plus immunotherapy regardless of PD-L1 status. In KEYNOTE-407, the results are positive in terms of response and overall survival, and quality of life is also improved. In IMpower132, some subgroups of patients showed a clear benefit from the combination therapy.Conclusion remarks: Dr. Novello believes that the future may be a new treatment approach not only based on chemotherapy alone or immunotherapy alone depending on PL-L1 expression, but combined chemotherapy plus immunotherapy.


More ESMO videos on Immuno-Oncology from the ESMO Channel

View the full playlist on the ESMO Channel

ESMO thanks the sponsor for supporting this track in 2019: